top of page
Companies in the News
Vir Biotech IDs Two Antibodies That Could Be Effective in Preventing and Treating COVID-19
San Francisco-based Vir Biotechnology indicated it has identified several human monoclonal antibody (mAb) candidates against SARS-CoV-2,...
Mar 25, 2020
CERo Therapeutics Announces Research Collaboration with Lyell Immunopharma and Completion of Series
Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors $40 Million Raised by CERo to Facilitate...
Mar 18, 2020
CERo Therapeutics Announces Research Collaboration with Lyell Immunopharma and Completion of Series
-- Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors -- -- $40 Million Raised by CERo to Facilitate...
Mar 18, 2020
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Xconomy Boston — Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48...
Feb 6, 2020
eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators...
Jan 9, 2020
Omniome Closes $60 Million Series C Financing to Advance Novel Genomic Sequencing Platform
Company Raises $145 Million in Eighteen Months to Complete Development and Early Commercialization of Breakthrough DNA Sequencing...
Jan 9, 2020
Indigo closes $200M financing to support continued growth of its platforms, including Indigo Grain M
Indigo raises an additional $200M, comprised of $175M in convertible equity and $25M in debt, bringing its total capital raised to...
Jan 6, 2020
Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combi
Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – GB1275 granted Orphan Drug Designation for...
Nov 12, 2019
Effector Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (EFT226) in Patient
Program addresses aggressive cancers with RTK (HER2, ERBB3, FGFR1, FGFR2) and KRAS mutations SAN DIEGO, November 5, 2019 — eFFECTOR...
Nov 5, 2019
bottom of page